Clinical Trial Update: PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of PF-04856884 (CVX-060) plus axitinib in previously treated metastatic renal cell carcinoma has been terminated; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• CVX-060
• PF-04856884

Snippet

Sponsor: Pfizer | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2016-01-18